Recruiting

New cancer drug versus standard chemotherapy for advanced bladder cancer

Plain-English translation of NCT07106762 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated July 2026 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

What is this trial?

This trial is testing a new medication called izalontamab brengitecan to see if it works better than standard platinum-based chemotherapy for advanced bladder cancer that has come back or gotten worse after immunotherapy. Researchers want to know if this medication can help people live longer and feel better than the standard treatment option. About 470 people will participate in this study.

Many people with advanced bladder cancer stop responding to immunotherapy treatments, and doctors need new options for these patients. This trial exists to find out whether this medication could be a more effective next step than the chemotherapy that is currently used.

Do you qualify?

You likely qualify if…

you have been diagnosed with advanced bladder cancer confirmed by a biopsy or pathology report
you have already received and progressed on an immunotherapy treatment for your cancer
you are physically well enough to receive chemotherapy treatment (ECOG performance status 0–1)
you have at least one tumor that can be measured on imaging scans
you have not received platinum-based chemotherapy in the past 12 months

You likely don't qualify if…

you have had any previous treatment with a drug similar to the one being tested (an ADC targeting EGFR or HER3)
you have had prior therapy with a topoisomerase 1 inhibitor
you have active brain metastases (cancer spread to the brain) that have not been treated
you have received more than 2 prior treatment regimens for your cancer
you received platinum-based chemotherapy within the last 12 months

What participation looks like

If you join this trial, you will be randomly assigned to receive either the new medication izalontamab brengitecan or standard platinum-based chemotherapy. You will visit the clinic regularly for treatment infusions, blood work, and imaging scans to monitor how your cancer is responding. The trial will track your health and side effects over time to compare how well each treatment works.

AI-generated summary from trial data · Jul 18, 2026 · Not medical advice

Trial locations(163 sites)

United States

Local Institution - 0167, Gilbert, Arizona

Local Institution - 0162, Fullerton, California

Palo Alto Center-Palo Alto Medical Foundation Research Institute, Palo Alto, California

Sutter Health - Sutter Institute for Medical Research, Sacramento, California

University of California Davis (UC Davis) Comprehensive Cancer Center, Sacramento, California